Premium
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine
Author(s) -
Van Leth F,
Hall DB,
Lange JMA,
Reiss P
Publication year - 2006
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2006.00390.x
Subject(s) - nevirapine , lamivudine , efavirenz , stavudine , medicine , virology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , hepatitis b virus , virus
Objectives To assess long‐term changes in lipids and lipoproteins concentrations associated with exposure to non‐nucleoside reverse transcriptase inhibitors. Methods Long‐term analysis of plasma lipid concentrations was performed in patients starting first‐line antiretroviral therapy with stavudine (d4T) and lamivudine, and either nevirapine or efavirenz. Results Concentrations of total cholesterol, low‐density lipoprotein cholesterol and triglycerides continued to increase, while high‐density lipoprotein cholesterol showed a slight decrease compared with earlier reported increases after 48 weeks. Conclusions Changes in body fat distribution expected to occur with continued exposure to d4T could offer a potential explanation for these findings.